MGC Pharmaceuticals Performance
| MGCLFDelisted Stock | USD 0.21 0.00 0.00% |
The company owns a Beta (Systematic Risk) of 0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, MGC Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding MGC Pharmaceuticals is expected to be smaller as well. MGC Pharmaceuticals at this time owns a risk of 0.0%. Please verify MGC Pharmaceuticals variance and the relationship between the maximum drawdown and day typical price , to decide if MGC Pharmaceuticals will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MGC Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable essential indicators, MGC Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 5.4 M | |
| Total Cashflows From Investing Activities | -1.1 M |
MGC |
MGC Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 21.00 in MGC Pharmaceuticals on September 14, 2024 and sell it today you would earn a total of 0.00 from holding MGC Pharmaceuticals or generate 0.0% return on investment over 90 days. MGC Pharmaceuticals is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded otc stocks are less volatile than MGC, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MGC Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MGC Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as MGC Pharmaceuticals, and traders can use it to determine the average amount a MGC Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MGCLF |
Based on monthly moving average MGC Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MGC Pharmaceuticals by adding MGC Pharmaceuticals to a well-diversified portfolio.
MGC Pharmaceuticals Fundamentals Growth
MGC OTC Stock prices reflect investors' perceptions of the future prospects and financial health of MGC Pharmaceuticals, and MGC Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MGC OTC Stock performance.
| Return On Equity | -2.19 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 24.97 M | |||
| Shares Outstanding | 2.87 B | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.81 X | |||
| Revenue | 4.65 M | |||
| EBITDA | (16.44 M) | |||
| Cash And Equivalents | 1.89 M | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.84 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (12.16 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 22.6 M | |||
About MGC Pharmaceuticals Performance
By analyzing MGC Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into MGC Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MGC Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MGC Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia. Mgc Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about MGC Pharmaceuticals performance evaluation
Checking the ongoing alerts about MGC Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for MGC Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MGC Pharmaceuticals is not yet fully synchronised with the market data | |
| MGC Pharmaceuticals has some characteristics of a very speculative penny stock | |
| MGC Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| MGC Pharmaceuticals has accumulated 4.35 M in total debt with debt to equity ratio (D/E) of 0.84, which is about average as compared to similar companies. MGC Pharmaceuticals has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MGC Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, MGC Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MGC Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MGC to invest in growth at high rates of return. When we think about MGC Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 4.65 M. Net Loss for the year was (20.35 M) with profit before overhead, payroll, taxes, and interest of 562.87 K. | |
| MGC Pharmaceuticals has accumulated about 1.89 M in cash with (12.16 M) of positive cash flow from operations. |
- Analyzing MGC Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MGC Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining MGC Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MGC Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MGC Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of MGC Pharmaceuticals' otc stock. These opinions can provide insight into MGC Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in MGC OTC Stock
If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |